Related Experiment Videos
Preventing hypophosphatemia during total parenteral nutrition
JPEN. Journal of Parenteral and Enteral Nutrition
|March 1, 1984
Summary
Phosphate supplementation is vital during total parenteral nutrition (TPN) to prevent hypophosphatemia. A dose of 13.6 mM phosphate/liter prevents it in most patients, but some require more.
Area of Science:
- Clinical Nutrition
- Metabolic Disorders
- Parenteral Therapy
Background:
- Phosphate is crucial during total parenteral nutrition (TPN).
- Individual phosphate needs vary, necessitating personalized supplementation strategies.
- Hypophosphatemia is a common complication in TPN patients.
Purpose of the Study:
- To determine the incidence of hypophosphatemia in TPN patients.
- To identify factors predicting the need for increased phosphate supplementation.
- To evaluate the efficacy of different phosphate supplementation levels in TPN.
Main Methods:
- Retrospective review of 68 TPN courses in 61 patients.
- Analysis of pre-TPN phosphate levels and development of hypophosphatemia during TPN.
- Comparison of hypophosphatemia incidence based on phosphate supplementation rates (6.8 mM vs. 13.6 mM/liter).
Main Results:
- 12% of patients were hypophosphatemic before TPN initiation.
- 42% of patients initiated with normal phosphate levels developed hypophosphatemia.
- Supplementation with 13.6 mM phosphate/liter prevented hypophosphatemia in most patients, unlike 6.8 mM/liter.
Conclusions:
- Hypophosphatemia is frequent in TPN despite supplementation.
- 13.6 mM phosphate/liter is generally effective, but higher needs exist for specific patient groups.
- Patients with hyperglycemia, insulin requirements, alcoholism, chronic weight loss, or diuretic/antacid use may need greater phosphate supplementation.